Coeliac disease vaccine trial underway
Proof-of-concept study will determine if the therapy can prevent the need for a gluten-free diet
1st November 2018
An international trial is underway to test a vaccine that will potentially end the need for patients with coeliac disease to adhere to gluten-free diets.
The Australian arm of the phase 2 trial of the peptide-based immunomodulatory vaccine therapy will be conducted in Melbourne, Perth, Adelaide and Brisbane.
The randomised, double-blind, placebo-controlled trial will look at the efficacy of a vaccine called Nexvax2 in adult subjects with confirmed coeliac disease who have been following a gluten-free diet for at least 12 consecutive months.